SMMT analyst estimates

Summit Therapeutics (SMMT) analyst ratings, the average price target and its range, and every firm's latest call.

SMMT analyst ratings and price targets

DateFirmCallTarget
Oct 1, 2026BarclaysSummit Therapeutics price target raised to $20 from $18 at Barclays$20.00
Sep 29, 2026JefferiesSummit Therapeutics plc (SMMT) PT Raised to $30 at Jefferies$30.00
Sep 29, 2026Goldman SachsGoldman Sachs Reiterates Buy Rating on Summit Therapeutics plc (SMMT)$41.00
Sep 9, 2026Summit Redstone PartnersSummit Therapeutics upgraded to Buy from Hold at Jefferies$25.00
Sep 8, 2026UBSUBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)$33.00
Aug 25, 2026Summit Redstone PartnersBernstein SocGen Group Upgrades Summit Therapeutics plc (SMMT) to Market Perform$11.90
Jul 24, 2026GuggenheimSummit Therapeutics price target lowered to $38 from $40 at Guggenheim$38.00
Jul 24, 2026Stifel NicolausSummit Therapeutics price target lowered to $38 from $45 at Stifel$38.00
Jul 24, 2026JefferiesSummit Therapeutics price target lowered to $15 from $17 at Jefferies$15.00
May 4, 2026H.C. WainwrightSummit Therapeutics price target lowered to $23 from $30 at H.C. Wainwright$23.00
May 1, 2026Piper SandlerSummit Therapeutics price target lowered to $16 from $17 at Piper Sandler$16.00
Feb 24, 2026H.C. WainwrightSummit Therapeutics price target lowered to $30 from $40 at H.C. Wainwright$30.00
Jan 14, 2026Piper SandlerH.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)$40.00
Dec 17, 2025Summit Redstone PartnersBarclays Upgrades Summit Therapeutics plc (SMMT) to Equalweight$18.00
Oct 21, 2025H.C. WainwrightSummit Therapeutics plc (SMMT) PT Lowered to $40 at H.C. Wainwright$40.00

Updated 2026-11-02 23:11 UTC